Top of the Street: EssilorLuxottica, BPER, UBS, DiaSorin, Lifco and Indutrade
11/02/2025 14:44
A round-up of notable broker activity this morning from Europe's
top-ranked* analysts:
** Jefferies upgrades EssilorLuxottica ESLX.PA to "buy"
from "hold," seeing the Franco-Italian eyewear maker's earnings
on the cusp of accelerating thanks to its new growth drivers in
AI and medical technology
** Citigroup cuts BPER Banca EMII.MI to "neutral" from
"buy" after bid on peer Banca Popolare di Sondrio BPSI.MI , the
brokerage seeing limited EPS benefits, a larger-than-simulated
capital impact and questions on combined ROTE
** Deutsche Bank raises Swiss peer UBS UBSG.S to "buy"
from "hold", saying the company continues to deliver strongly on
cost cutting and significant capital return increase, remains in
the right businesses for 2025 and beyond
INITIATIONS AND REINSTATEMENTS
** DB starts Italian medical diagnostic group DiaSorin
DIAS.MI with "buy" and PT of EUR 121, cites "XL growth with
multiPLEX opportunities", strong profitable growth track record,
attractive valuation, upcoming catalysts such as launches and
partnerships, expects co to outperform its end markets
** UBS initiates Lifco LIFCOb.ST with rating "buy" and TP
of SEK 420, flagging a "quality stock" among Swedish acquirers,
expecting co to continue delivering about 9% pa acquired
revenues mid-term
** The brokerage also starts coverage on Indutrade INDT.ST
with "buy" rating and PT of SEK 400, naming it its value stock
among Swedish serial acquirers, pointing to co's acquired
revenues of about 7% pa and further margin expansion
(*Analyst rankings from Thomson Reuters StarMine. The scale is
from 1-star to 5-star with 5 being the best. Analysts are ranked
on earnings accuracy as well as relative performance of
recommendations over trailing 12-month & 24-month periods.)
($1 = 0.9695 euros)
(Reporting by Olivier Cherfan & Clément Martinot)
((olivier.cherfan@thomsonreuters.com ;
clement.martinot@thomsonreuters.com))